Wednesday, November 18, 2026
  • About Us
  • Advertise
  • Privacy & Policy
  • Team
  • Contact
The English Chronicle
Advertisement
  • Home
  • Business & Economy
  • Politics
  • Entertainment
  • Sports
  • Science & Technology
  • UK News
  • World News
  • Health
No Result
View All Result
  • Home
  • Business & Economy
  • Politics
  • Entertainment
  • Sports
  • Science & Technology
  • UK News
  • World News
  • Health
No Result
View All Result
The English Chronicle
No Result
View All Result

Viagra-Like Pill Offers Hope in Alzheimer’s Fight

10 minutes ago
in Education, Health, Latest, Life & Society, Science & Technology
Viagra-Like Pill Offers Hope in Alzheimer’s Fight
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter
Published: 18 November 2026. The English Chronicle Desk. The English Chronicle Online

A promising development in Alzheimer’s disease research has raised hopes of a new approach to slowing the progression of memory loss and cognitive decline. An experimental daily tablet called AR1001, which belongs to the same family of medicines as Viagra, has demonstrated the potential to slow the deterioration of memory and thinking abilities in people with early-stage Alzheimer’s disease, according to findings from an international clinical trial.

Researchers reported that the medication slowed cognitive decline by approximately 31 per cent among a specific group of patients who were not receiving other commonly used Alzheimer’s treatments. The findings have attracted considerable attention from medical researchers and dementia specialists, who believe the drug could represent an important development in the search for alternative treatments for the disease.

However, experts have emphasised that the results require careful interpretation. Although the trial produced encouraging findings in a particular patient group, the medication did not demonstrate statistically significant benefits across the entire study population. Further research will therefore be necessary to establish its effectiveness, safety and potential role in future Alzheimer’s treatment.

The findings were presented at the Clinical Trials on Alzheimer’s Disease conference in Boston, where researchers discussed the results of the international stage-three clinical trial. The research involved participants from 13 countries, including the United Kingdom, making it an important investigation into a potential new treatment for one of the world’s most challenging neurological conditions.

Alzheimer’s disease is the most common form of dementia and gradually damages the brain, affecting memory, thinking, communication and the ability to carry out everyday activities. As the disease progresses, patients may experience increasing difficulty recognising familiar people, remembering important information, making decisions and managing routine responsibilities. The condition also places considerable emotional and financial pressure on families and caregivers.

The global burden of dementia is expected to increase substantially over the coming decades. Forecasts suggest that approximately 153 million people worldwide could be living with dementia by 2050. With no definitive cure currently available for Alzheimer’s disease, researchers are exploring different medical approaches to slow its progression and preserve patients’ quality of life for as long as possible.

AR1001 is being developed by South Korean pharmaceutical company AriBio. It belongs to a class of medicines known as phosphodiesterase-5 inhibitors, commonly referred to as PDE5 inhibitors. Viagra, widely used to treat erectile dysfunction, belongs to the same drug family.

These medicines work by influencing specific biological processes that help relax blood vessels and improve blood circulation. Researchers believe that AR1001 may help Alzheimer’s patients by increasing blood flow to the brain, potentially supporting the delivery of oxygen and nutrients to important brain regions.

However, scientists believe its potential effects may extend beyond improving circulation. The medication could also influence biological pathways within brain cells associated with learning, memory and other cognitive functions. This combination of possible effects has made AR1001 particularly interesting to researchers investigating new ways to address Alzheimer’s disease.

According to the company, the study included 604 people with early-stage Alzheimer’s disease who were not taking other medications specifically used to treat the condition. Among this group, AR1001 demonstrated a statistically significant slowing of clinical decline, with the reported benefit reaching approximately 31 per cent.

The findings suggest that the medication could help preserve cognitive abilities over the period examined in the trial. For patients and families dealing with Alzheimer’s disease, even a relatively modest delay in the progression of symptoms could potentially provide additional time for maintaining independence, participating in family life and managing everyday activities.

Nevertheless, the results were not equally positive across all participants. When researchers examined a broader group of patients who were also taking other medications for Alzheimer’s symptoms, AR1001 did not achieve statistically significant results. This difference raises important questions about whether the drug works differently depending on a patient’s existing treatment, disease characteristics or other medical factors.

Researchers will need to investigate these differences in greater detail before determining which patients might benefit most from the medication. The findings also highlight the complexity of Alzheimer’s disease, which involves multiple biological processes rather than a single identifiable cause.

Professor Tara Spires-Jones, a professor of neurodegeneration at the University of Edinburgh and a fellow of the Academy of Medical Sciences, described the results as very promising. She explained that the medication appeared to work by increasing blood flow while potentially stimulating pathways inside brain cells that support learning and memory.

Her assessment reflects growing interest in treatments that target different aspects of Alzheimer’s disease rather than concentrating exclusively on one biological mechanism. Although improving blood circulation does not necessarily reverse existing brain damage, supporting the functioning of brain cells could potentially help slow the deterioration associated with the condition.

Dr Sheona Scales, director of research at Alzheimer’s Research UK, also welcomed the findings, describing them as very encouraging and an important milestone in the search for new treatments.

She highlighted the fact that AR1001 uses a different approach from several existing disease-modifying Alzheimer’s medicines. Rather than directly targeting amyloid, a protein that accumulates in the brains of many people with Alzheimer’s disease, the experimental medication acts on a particular enzyme and influences several biological processes involved in brain function.

According to Scales, the statistically significant findings among participants who were not taking other commonly prescribed Alzheimer’s medications were particularly noteworthy. However, she stressed that the absence of a significant benefit across the entire trial population means researchers must continue examining the results before drawing firm conclusions about the drug’s overall effectiveness.

Dr Richard Oakley, associate director of research and innovation at the Alzheimer’s Society, also described the preliminary findings as exciting. He suggested that AR1001 could potentially represent a new treatment approach for early Alzheimer’s disease, particularly because it appears to target processes associated with the disease rather than simply addressing individual symptoms.

One of the medication’s notable features is its administration. Unlike some existing treatments that require injections or more complicated medical arrangements, AR1001 is designed as a once-daily oral tablet. If further research confirms its effectiveness and safety, this could make treatment more convenient for patients and their families.

Oakley also highlighted the reported safety findings, noting that the side-effects observed during the trial were generally mild to moderate. However, a favourable safety profile in a clinical trial does not automatically establish that a medication is suitable for widespread or long-term use. Larger investigations and regulatory assessments will be necessary to understand its risks more fully.

The comparison with Viagra has attracted public attention because both medicines belong to the same pharmaceutical family. However, specialists have warned against interpreting this connection as evidence that Viagra itself can prevent or treat Alzheimer’s disease.

AR1001 is a separate experimental medication being developed specifically for Alzheimer’s disease. Its potential effects, dosage, safety and clinical application must be assessed independently. Medical experts have therefore advised people not to take Viagra or other PDE5 inhibitors in an attempt to prevent memory loss or treat dementia without appropriate medical guidance.

The latest findings also highlight a broader change in Alzheimer’s research. For many years, scientific investigations have concentrated heavily on amyloid-related treatments. Although some newer medicines have demonstrated the ability to slow disease progression in certain patients, researchers continue to explore alternative approaches involving blood circulation, inflammation, cellular activity and other biological mechanisms.

AR1001 could contribute to this wider effort if subsequent studies confirm the benefits suggested by the latest trial. Nevertheless, researchers must establish whether the observed improvement can be consistently reproduced, how long the benefits might last and whether the medication offers meaningful advantages for patients at different stages of the disease.

Further independent scientific scrutiny will also be essential. The complete trial findings will need to be examined by researchers, medical professionals and regulatory authorities before the treatment can be considered for routine clinical use. Regulators will assess the strength of the evidence, the medication’s safety profile and whether its potential benefits outweigh its risks.

For millions of families affected by Alzheimer’s disease, the possibility of a new treatment offers considerable hope. The condition can gradually change relationships, reduce independence and place enormous responsibilities on relatives who provide daily care. A medication capable of slowing cognitive decline could potentially help patients retain important abilities for longer, although the extent of any real-world benefit remains uncertain.

The AR1001 findings do not yet establish a cure or confirm that the drug will become an approved treatment. However, they provide an encouraging indication that targeting different biological processes may open new possibilities in Alzheimer’s research. As further studies progress, the scientific community will be watching closely to determine whether this Viagra-like experimental tablet can become a meaningful addition to the future treatment of dementia.

Related News:

How Bringing Forests Into Preschools Boosts Children’s HealthHow Bringing Forests Into Preschools Boosts Children’s Health No link found between paracetamol in pregnancy and autismNo link found between paracetamol in pregnancy and autism Canadian astronaut French words ease language rowCanadian astronaut French words ease language row NHS Safety Fears as Nurses Cover Doctor GapsNHS Safety Fears as Nurses Cover Doctor Gaps Older Than Dinosaurs: Secrets of Mayfly Dance RevealedOlder Than Dinosaurs: Secrets of Mayfly Dance Revealed Study Launches Into Brain Injury Risks in Women’s RugbyStudy Launches Into Brain Injury Risks in Women’s Rugby UK Schools Struggle as Classrooms Top 40CUK Schools Struggle as Classrooms Top 40C Weight-Loss Drugs Offer Food Savings Mainly to High EarnersWeight-Loss Drugs Offer Food Savings Mainly to High Earners English Hospitals Face Shortage of Health Play StaffEnglish Hospitals Face Shortage of Health Play Staff Headteachers Warn New Ofsted System Is Harming WellbeingHeadteachers Warn New Ofsted System Is Harming Wellbeing Africa Urged to Transform Universities for Young TalentAfrica Urged to Transform Universities for Young Talent Banned Health Coach Faces UK Events CriticismBanned Health Coach Faces UK Events Criticism Kagan and Soai Win 2026 Nobel Chemistry PrizeKagan and Soai Win 2026 Nobel Chemistry Prize WHO Seeks Russia Answers Over Suspected Plague DeathWHO Seeks Russia Answers Over Suspected Plague Death Sardinia Village Emerges as Longevity HotspotSardinia Village Emerges as Longevity Hotspot Teenager Receives UK’s First Testicular Tissue TransplantTeenager Receives UK’s First Testicular Tissue Transplant Controversial Vaccine Trial Approved in Guinea-BissauControversial Vaccine Trial Approved in Guinea-Bissau Australian Advocates Seek Subsidised Drugs for PMOSAustralian Advocates Seek Subsidised Drugs for PMOS Indonesia Tests Dry Ice as Toxic Haze Spreads Across AsiaIndonesia Tests Dry Ice as Toxic Haze Spreads Across Asia Climate Change Makes Tap Water Unsafe in Arctic NorwayClimate Change Makes Tap Water Unsafe in Arctic Norway Up to 20 English Maternity Units Face Possible ClosureUp to 20 English Maternity Units Face Possible Closure Support for NHS Founding Principles Declines Across UKSupport for NHS Founding Principles Declines Across UK Nigeria Confirms Ebola Case as Regional Outbreak SpreadsNigeria Confirms Ebola Case as Regional Outbreak Spreads Democrats Court Maha Voters as Trump Alliance FraysDemocrats Court Maha Voters as Trump Alliance Frays Australia Faces Growing Scrutiny Over Paraquat RisksAustralia Faces Growing Scrutiny Over Paraquat Risks UK Weighs Tougher Firework Rules Over Animal WelfareUK Weighs Tougher Firework Rules Over Animal Welfare NHS Rolls Out Child Illness Warning System Across EnglandNHS Rolls Out Child Illness Warning System Across England Measles Claims Child’s Life in New York After 30 YearsMeasles Claims Child’s Life in New York After 30 Years Queensland Hospital to Close Labs After Safety ProbeQueensland Hospital to Close Labs After Safety Probe Cumbria Mental Health Hub Shows Early PromiseCumbria Mental Health Hub Shows Early Promise UK Review Urges Jobs Revolution for Disabled YouthUK Review Urges Jobs Revolution for Disabled Youth AI Crisis Forces UK Universities to Rethink ExamsAI Crisis Forces UK Universities to Rethink Exams Hundreds of English Children Receive Weight-Loss DrugsHundreds of English Children Receive Weight-Loss Drugs Exam System Failure Disrupts Melbourne University TestsExam System Failure Disrupts Melbourne University Tests Patients to Test Health at Home to Ease NHS Winter PressurePatients to Test Health at Home to Ease NHS Winter Pressure Working-Class Men with Prostate Cancer Left Behind by NHSWorking-Class Men with Prostate Cancer Left Behind by NHS New AI tool could cut wasted efforts in organ transplantsNew AI tool could cut wasted efforts in organ transplants Healthy Habits in Your 30s That Boost Life in Your 70sHealthy Habits in Your 30s That Boost Life in Your 70s Parents Claim Damages Following Carbon Monoxide Exposure in SchoolScottish Families Take Legal Action Over School CO Leak Coffins Now Too Large to Cremate Amid Rising Obesity CrisisCoffins Now Too Large to Cremate Amid Rising Obesity Crisis AI health summariesGoogle Removes Some AI Health Summaries Over Safety Concerns autistic girlsAutistic Girls Often Missed in Childhood Diagnoses, Study Finds statin side-effectsMost Statin Side-Effects Are Not Caused by Drugs, Study Confirms ZorevunersenZorevunersen Breakthrough for Dravet Syndrome cancer death rateCancer Death Rate in Britain Falls by Nearly a Third multivitaminsTaking Multivitamins Daily Could Slightly Slow Ageing, Study Finds ‘Drinking from a Fetid Pond’: Superbug Genes in Lough Neagh‘Drinking from a Fetid Pond’: Superbug Genes in Lough Neagh Exhibition Revisits Life of 18th-Century Black Court FigureExhibition Revisits Life of 18th-Century Black Court Figure WHO approves first malaria drug for babiesWHO approves first malaria drug for babies Barrister Criticises Trial After Suicide Case VerdictBarrister Criticises Trial After Suicide Case Verdict Pope Meets Families in Italy Toxic Waste ZonePope Meets Families in Italy Toxic Waste Zone Tech Trends and the Battle Against Exam Hall CheatingTech Trends and the Battle Against Exam Hall Cheating Deadly H5 Bird Flu Reaches Australia's East CoastDeadly H5 Bird Flu Reaches Australia’s East Coast British Teens in EU Face Soaring UK University FeesBritish Teens in EU Face Soaring UK University Fees London Tube Heat Reaches Dangerous LevelsLondon Tube Heat Reaches Dangerous Levels Gen Z turns to BirdTok for a gentler digital escapeGen Z turns to BirdTok for a gentler digital escape Nathan Cofnas Ghent UniversityGhent Professors Questioned Cofnas Appointment back-to-work blues# How to Beat the Back-to-Work Blues After Summer Fiji Declares National HIV Emergency as Cases SurgeFiji Declares National HIV Emergency as Cases Surge Essential Books for Understanding the AI DebateEssential Books for Understanding the AI Debate Tropics May Wait Longest for Net-Zero Climate BenefitsTropics May Wait Longest for Net-Zero Climate Benefits Drones Could Speed Up Defibrillator DeliveryDrones Could Speed Up Defibrillator Delivery London Facial Recognition Trial Ends With False AlertLondon Facial Recognition Trial Ends With False Alert UK University Strikes Spread as Financial Pressure GrowsUK University Strikes Spread as Financial Pressure Grows French School Protests Escalate as 400 Schools CloseFrench School Protests Escalate as 400 Schools Close UK Water Firms Earn Millions From Industrial WastewaterUK Water Firms Earn Millions From Industrial Wastewater UK Pharmacy Body Drops Teva After Ethical ConcernsUK Pharmacy Body Drops Teva After Ethical Concerns French Students Protest Poor Conditions in Paris SuburbsFrench Students Protest Poor Conditions in Paris Suburbs Elizabeth Struhs Inquest Examines Child Safety FailuresElizabeth Struhs Inquest Examines Child Safety Failures Greta Thunberg Backs French Students in School ProtestsGreta Thunberg Backs French Students in School Protests UK Shoppers Urged to Avoid Hake and ColeyUK Shoppers Urged to Avoid Hake and Coley Senegal LGBTQ+ Crackdown Drives People Into HidingSenegal LGBTQ+ Crackdown Drives People Into Hiding NHS Trusts Reject Palantir’s £330m Patient Data PlatformNHS Trusts Reject Palantir’s £330m Patient Data Platform Zelenskyy Says US Failed to Warn Kyiv of Russian StrikesZelenskyy Says US Failed to Warn Kyiv of Russian Strikes Nearly One in Four European Pilots Fly While FatiguedNearly One in Four European Pilots Fly While Fatigued Yvette Cooper Reverses NHS Patient Watchdog Abolition PlanYvette Cooper Reverses NHS Patient Watchdog Abolition Plan UK Employers to Be Forced to Publish Job SalariesUK Employers to Be Forced to Publish Job Salaries CEU Eyes Budapest Return as Hungary Enters New EraCEU Eyes Budapest Return as Hungary Enters New Era UK Blood Services Urge 150,000 Donations Ahead of WinterUK Blood Services Urge 150,000 Donations Ahead of Winter NSW Inquest Examines Deaths of Twins After Free BirthNSW Inquest Examines Deaths of Twins After Free Birth

STAY CONNECTED

  • 6k Fans
  • 450 Followers
  • 600 Subscribers

MOST POPULAR

Minor No-Fault Accident Sends Car Insurance Quote Soaring

Minor No-Fault Accident Sends Car Insurance Quote Soaring

22 hours ago
Imperial Brands to Cut 4,600 Jobs Amid AI Expansion

Imperial Brands to Cut 4,600 Jobs Amid AI Expansion

22 hours ago
UK Unemployment Falls to 4.6% Amid Youth Jobs Crisis

UK Unemployment Falls to 4.6% Amid Youth Jobs Crisis

22 hours ago
Burnham Says Brexit Has Weakened Britain's Global Standing

Burnham Says Brexit Has Weakened Britain’s Global Standing

1 day ago
Millions of UK Phones to Receive Nationwide Emergency Alert Test on Sunday

Millions of UK Phones to Receive Nationwide Emergency Alert Test on Sunday

September 6, 2025
GSK cancer drug shows early promise in trials

GSK cancer drug shows early promise in trials

April 12, 2026
Load More

About Us

The English Chronicle

The English Chronicle is your trusted source for accurate, timely, and unbiased news. Based in the heart of the digital age, our mission is to deliver well-researched journalism that informs, engages, and empowers readers across the globe.

Address:-
UK Address: Harbour House, Cold Harbour Lane, Rainham, London Borough of Havering, United Kingdom. RM13 9YB

Browse by Category

  • Africa
  • Agriculture
  • Ai and Innovation
  • Animal Rights
  • Animals
  • Arts And Culture
  • Asia Pacific
  • Australia News
  • Books & Literature
  • Business & Economy
  • Canada News
  • Child Health
  • Child Safety
  • Climate Change
  • Companies
  • Cricket
  • Crime
  • Defence And Military
  • Economics
  • Education
  • Energy
  • Entertainment
  • Environment
  • Europe
  • Fashion
  • FIFA
  • Finance
  • Food
  • Football
  • Health
  • History
  • Human Rights
  • Infrastructure
  • innovation
  • International
  • Investigative Stories
  • Ireland
  • Latest
  • Law
  • Life & Society
  • Maritime
  • Market
  • Media
  • Medical Innovation
  • Middle East
  • Music
  • National Security
  • Natural Disaster
  • Opinion
  • Politics
  • Post
  • Premier League
  • Public Safety
  • Real Estate and Property
  • Religion
  • Retail
  • Retail
  • Royal Family
  • Science & Technology
  • Scotland and Highlands
  • South Asia
  • Space
  • Sports
  • Tech News
  • Tennis
  • Tourism and Economy
  • Transport
  • Travel
  • TV & Film
  • UEFA
  • UK News
  • US News
  • Violence
  • War and Conflict
  • Weather
  • Wild Life
  • World News
Rubio Rejects Links Between US Tech Outages

Rubio Rejects Links Between US Tech Outages

3 minutes ago
Viagra-Like Pill Offers Hope in Alzheimer’s Fight

Viagra-Like Pill Offers Hope in Alzheimer’s Fight

9 minutes ago
Mary Peltola’s Alaska Win Gives Democrats 56 Senate Seats

Mary Peltola’s Alaska Win Gives Democrats 56 Senate Seats

17 minutes ago
Imperial Brands to Cut 4,600 Jobs Amid AI Expansion

Imperial Brands to Cut 4,600 Jobs Amid AI Expansion

22 hours ago
  • About Us
  • Advertise
  • Privacy & Policy
  • Team
  • Contact

© 2025 The English Chronicle.

No Result
View All Result
  • Home
  • Business & Economy
  • Politics
  • Entertainment
  • Sports
  • Science & Technology

© 2025 The English Chronicle.